^
Association details:
| Biomarker: | YAP1 overexpression + WWTR1 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + CA3 (YAP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)
Published date:
05/31/2022
Excerpt:
Out of six patient-derived HCC cell lines, cell lines with high YAP/TAZ expression at the MCTS level responded more sensitively to the combination therapy (Sorafenib + CA3 0.1 μM) despite the potent cytotoxic effect of CA3 exhibited in all of the patient-derived HCCs.
DOI:
10.3390/cancers14112733
